Shimrit Ringelstein-Harlev

7PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

Hazim Khatib, Amit Parizat, Jabour Halloun

|Sep 15, 2025
Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.

Michal Nordkin, Nashwa Fadaos, Ronit Leiba

|Jun 27, 2025
CCR5 predicts neurotoxicity in CAR-T-cell therapy.

Ayal Rozenberg, Shahar Shelly, Raz Winer

|Dec 11, 2024
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab.

Nashwa Fadaos, Yossi Ben Dor, Tehila Azoulay

|Mar 25, 2023
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.

Ofrat Beyar Katz, Chava Perry, Sigal Grisariu-Greenzaid

|Dec 08, 2022
In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T-cell inhibitory properties, contributing to immunosuppression.

Shimrit Ringelstein-Harlev, Mona Fanadka, Netanel A Horowitz

Pageof 2

Frequent Collaborators

4 joint publications

Tsila Zuckerman

2 joint publications

Netanel A Horowitz

2 joint publications

Eldad J Dann

1 joint publications

Ofrat Beyar Katz